

Special Issue

Thymic Carcinoma

Message from the Guest Editor

Thymic epithelial tumors, which are generally classified as thymomas and thymic carcinomas, are uncommon neoplasms presenting in less than 2.0% of all malignancies. In particular, thymic carcinoma is a rare neoplasm with a dismal outcome and no available therapeutic agents for its advanced form. Therefore, the identification of new targets that can serve as predictive and prognostic markers for the development of an optimal treatment plan is essential. To treat thymic cancer, surgery, radiotherapy and chemotherapy are chosen according to its expansion. Surgical resection is absolutely suitable for early disease, but it is hard to cure the patients with advanced disease by systemic chemotherapy or radiotherapy. Meanwhile, it is of critical importance to develop predictive biomarkers (e.g., PET as an indicator of metabolic activity) and different kinds of pathologic markers. Molecular imaging techniques have been under recent development in oncology. An optimal approach realizes the improvement of curative treatment of thymic carcinoma. The scope of this Special Issue includes the therapeutic significance of new modalities, molecular imaging and optimal biomarkers.

Guest Editor

Dr. Kyoichi Kaira

Department of Respiratory Medicine, Comprehensive Cancer Center,
International Medical Center, Saitama University Hospital, 1397-1
Yamane, Hidaka-City, Saitama 350-1298, Japan

Deadline for manuscript submissions

closed (28 November 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/59534

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)